3920-40-9

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazole-3-carboxamide,4-amino-1-methyl-(9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique ring structure and functional groups make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, 1H-Pyrazole-3-carboxamide,4-amino-1-methyl-(9CI) serves as a versatile starting material for the preparation of a wide range of organic compounds. Its reactivity and structural features allow for the creation of diverse chemical entities, which can be further utilized in various applications, such as the development of new materials or the synthesis of complex molecules.

InChI:InChI=1/C5H8N4O/c1-9-2-3(6)4(8-9)5(7)10/h2H,6H2,1H3,(H2,7,10)

Upstream product

• 3920-39-6 1-methyl-4-nitro-1H-pyrazole-3-carboxamide 
• 400877-57-8 1-methyl-4-nitro-1H-pyrazole-3-carboxylic acid methyl ester 

Downstream Products

• 1161375-01-4 N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-2-(3-methanesulfonyl-phenyl)thiazole-4-carboxamide 
• 1357086-83-9 5-{[(4-methoxy-phenyl)carbamoyl]amino}-8-(furan-2-yl)-2-methyl-2H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine 

Relevant academic research and scientific papers

Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma

Harboring MYD88 L265P mutation triggers tumors growth through the activation of NF-κB by interleukin-1 receptor associated kinase 4 (IRAK4) in diffuse large B-cell lymphoma (DLBCL), highlighting IRAK4 as a therapeutic target for tumors driven by aberrant MYD88 signaling. Herein, we report the design, synthesis, and structure?activity relationships of imidazo[1,2-b]pyridazines as potent IRAK4 inhibitors. The representative compound 5 exhibited excellent IRAK4 potency (IRAK4 IC50 = 1.3 nM) and favorable kinase selectivity profile. It demonstrated cellular selectivity for activated B cell–like (ABC) subtype DLBCL with MYD88 L265P mutation in cytotoxicity assay. The kinase inhibitory efficiency of compound 5 was further validated by Western blot analysis of phosphorylation of IRAK4 and downstream signaling in OCI-LY10 and TMD8 cells. Besides, combination of compound 5 and BTK inhibitor ibrutinib synergistically reduced the viability of TMD8 cells. These results indicated that compound 5 could be a promising IRAK4 inhibitor for the treatment of mutant MYD88 DLBCL.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

Imidazopyridazine IRAK4 inhibitor, and preparation method and application thereof

The invention belongs to the field of medicines, and especially relates to an imidazopyridazine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an applicationof a medicinal composition of the compound or the salt in the treatment of tumors, inflammations, immunity and other diseases. The imidazopyridazine compound is a novel protein kinase IRAK4 inhibitor, and can selectively inhibit IRAK4 and downstream signaling pathways thereof. The compound has the structural formula I.

Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists

The discovery and development of adenosine receptor antagonists have represented for years an attractive field of research from the perspective of identifying new drugs for the treatment of widespread disorders such as inflammation, asthma and Parkinson's

NITROGEN CONTAINING HETEROARYL COMPOUNDS

The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, R1, R2, R3, R4, R5 and R6 are as defined in the descripti

NITROGEN CONTAINING HETEROARYL COMPOUNDS

The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, (a), R1, R2, R3, R4, R5 and R6 are as defined in the desc